ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure | Biogen
Biogen and UCB reported that dapirolizumab pegol (DZP) showed higher response rates in SLE patients using the novel TRM-SLE measure in a Phase 3 study. DZP plus standard care achieved greater TRM-SLE-50 (61.2% vs 43.2%) and TRM-SLE-100 (52.5% vs 36.8%) responses than placebo. Separate analyses showed sustained low disease activity and remission with DZP.
How this was made
The 30-second read
Why it matters
The disclosed response‑rate improvements and sustained low disease activity suggest a potentially market‑moving development for both Biogen and UCB.
Market read
First public disclosure of improved efficacy metrics for a late‑stage SLE therapy, likely to influence biotech valuations.
What to watch
Regulatory acceptance of the novel TRM‑SLE endpoint remains uncertain, which could temper upside.
Background
The article reports new post‑hoc analyses of the Phase 3 PHOENYCS GO trial for dapirolizumab pegol, presented at the ACR 2026 meeting.
Ticker impact
Biogen announced post‑hoc Phase 3 data showing dapirolizumab pegol achieved higher response rates versus placebo in SLE.
likely upward pressure as investors price in improved efficacy signals
The new response‑rate numbers are materially better than placebo and represent the first public disclosure of this analysis.
Market effects
Positive SLE trial data could lift sentiment for biotech firms developing autoimmune therapies.
European biotech stocks may see modest gains as UCB benefits.
The data add confidence to the pipeline of biologics targeting systemic lupus erythematosus.
Counterpoint
Investors may question the post‑hoc nature of the analysis and await confirmatory primary endpoints before committing.
Key entities
- CompanyBiogen Inc.
US‑listed biotech (NASDAQ: BIIB) co‑developer of dapirolizumab pegol.
- CompanyUCB
European biotech (Euronext Brussels: UCB) co‑developer of the drug.
.webp&w=2048&q=75)
